Results 61 to 70 of about 1,127,554 (354)

Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC‐ESCC2019): A multicenter, phase 2 study

International Journal of Cancer, 2022
Optimal treatment for resectable esophageal squamous cell carcinoma (ESCC) is controversial, especially in the context of potential benefit of combining PD‐1 blockade with neoadjuvant therapy.
Jun Liu, Jingpei Li, Wanli Lin, D. Shao, L. Depypere, Zhifeng Zhang, Zhuoyi Li, F. Cui, Zesen Du, Yuan Zeng, Shunjun Jiang, P. He, X. Gu, Huai Chen, Hai Zhang, Xiaowei Lin, Haoda Huang, Wenqiang Lv, Weiming Cai, W. Liang, Hengrui Liang, Wenxi Jiang, Wei Wang, Ke Xu, W. Cai, Kui Wu, T. Lerut, Jun-hui Fu, Jianxing He   +28 more
semanticscholar   +1 more source

Neoadjuvant chemotherapy in breast cancer

British Journal of Surgery, 2005
Abstract Background Neoadjuvant chemotherapy for breast cancer was originally used in locally advanced inoperable disease in order to achieve surgical resection. It was then extended to operable breast cancer with a view to downstaging tumours to facilitate breast-conserving surgery.
Charfare, H, Limongelli, S, Purushotham, A D   +2 more
openaire   +3 more sources

Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial

Nature Medicine
Recent single-arm studies involving neoadjuvant camrelizumab, a PD-1 inhibitor, plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (LA-ESCC) have shown promising results.
J. Qin, Liyan Xue, Anlin Hao, Xiaofeng Guo, Tao Jiang, Yunfeng Ni, Shuoyan Liu, Yujie Chen, Hongjing Jiang, Chen Zhang, M. Kang, Ji-hong Lin, Hecheng Li, Chengqiang Li, H. Tian, Lin Li, Junke Fu, Yong Zhang, Jianqun Ma, Xiaoyuan Wang, Maoyong Fu, Hao Yang, Zhaoyang Yang, Yongtao Han, Longqi Chen, L. Tan, Tianyang Dai, Yongde Liao, Weiguo Zhang, Bin Li, Qixun Chen, Shiping Guo, Y. Qi, Li Wei, Zhigang Li, Ziqiang Tian, X. Kang, Ruixiang Zhang, Yong Li, Zhen Wang, Xiankai Chen, Z. Hou, Rongrong Zheng, Wenqing Zhu, Jie He, Yin Li   +45 more
semanticscholar   +1 more source

Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: A multi-center real-world retrospective study

Cell Reports Medicine, 2022
Summary To parallelly compare the efficacy of neoadjuvant immunotherapy (tislelizumab), neoadjuvant chemotherapy (gemcitabine and cisplatin), and neoadjuvant combination therapy (tislelizumab + GC) in patients with muscle-invasive bladder cancer (MIBC ...
Jiao Hu, Jinbo Chen, Zhenyu Ou, Haige Chen, Zheng Liu, Minfeng Chen, Ruiyun Zhang, Anze Yu, Rui Cao, Enchong Zhang, Xi Guo, B. Peng, D. Deng, Chunliang Cheng, Jinhui Liu, Huihuang Li, Yihua Zou, Ruoping Deng, Gang Qin, Wenze Li, Lue Wang, Tao Chen, Xiaming Pei, G. Gong, Jiansheng Tang, Belaydi Othmane, Z. Cai, Chunyu Zhang, Zhi Liu, X. Zu   +29 more
semanticscholar   +1 more source

Neoadjuvant chemotherapy with dose dense MVAC is associated with improved survival after radical cystectomy compared to other cytotoxic regimens: A tertiary center experience

PLoS ONE, 2021
Introduction Neoadjuvant chemotherapy has become standard of care for cisplatin-eligible patients with muscle-invasive bladder cancer qualified to radical cystectomy, providing a modest increase in 5-year overall survival rate. Several regimens are being
Artur Lemiński, Krystian Kaczmarek, Tomasz Byrski, Marcin Słojewski   +3 more
doaj   +2 more sources

Preoperative radiotherapy in patients with locally advanced esophageal squamous cell carcinoma: a narrative review

Frontiers in Oncology
Neoadjuvant treatments play a crucial role in improving survival rates for patients with locally advanced resectable esophageal cancer. The CROSS and NEOCRTEC5010 trials have shown that neoadjuvant concurrent chemoradiotherapy significantly enhances ...
Yan Lin, Shou-Feng Wang, Huan-Wei Liang, Yang Liu, Wei Huang, Xin-Bin Pan   +5 more
doaj   +1 more source

Outcomes and Surgical Management of Malignant Rhabdoid Tumor of the Kidney: A Report From the Pediatric Surgical Oncology Research Collaborative

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Purpose Malignant rhabdoid tumor of the kidney (MRTK) is a rare, aggressive tumor seen in young children. The optimal timing of resection for locally advanced tumors is not well‐defined. The purpose of this study is to evaluate modern oncologic outcomes and the impact of surgical timing. Methods A multicenter retrospective review was performed
Hannah N. Rinehardt, Elisabeth T. Tracy, Anghela Paredes, Catherine Beckhorn, Harold J. Leraas, Joseph Fusco, Katlyn G. McKay, Nelly‐Ange T. Kontchou, Zachary J. Kastenberg, David W. Hoyt, Jonathan Roach, Emily K. Myers, Nicholas G. Cost, Bhargava Mullapudi, Charles R. Marchese, Amanda R. Jensen, Timothy B. Lautz, Michela Carter, Roshni Dasgupta, John Lundstedt, Joseph G. Brungardt, Lindsay Talbot, Andrew M. Davidoff, Andrew J. Murphy, Jennifer H. Aldrink, Sara Mansfield, Nelson Piche, Annie Le‐Nguyen, Dave R. Lal, Brian T. Craig, Jennifer M. Schuh, Barrett P. Cromeens, Sindhu Mannava, Shannon Castle, Adriana Lopez, Kelsey Mello, Joshua Short, Robin T. Petroze, Shay Rajaval, Grace R. Thompson, Peter Mattei, David H. Rothstein, Elizabeth Fialkowski, Kathryn Fowler, Nathan Martchenke, Barrie S. Rich, Richard D. Glick, Erin G. Brown, Kathleen Doyle, Paige Abril, Natashia Seemann, Jacob Davidson, Claire A. Wilson, Hau D. Le, Devashish Joshi, Michael Stellon, Tamer Ahmed, Alexandra Dimmer, Peter F. Ehrlich, Maya Hammoud, Keyonna Williams, Christa N. Grant, Merit Gorgy, Stephanie F. Polites, Julia Debertin, Danielle B. Cameron, Alyssa Stetson, Eugene S. Kim, William G. Lee, Aaron Barkhordar, Mary Austin, Brian A. Coakley, Anastasia Kahan, Joseph T. Murphy, Michael Pitonak, Chloé Boehmer, Marcus M. Malek   +76 more
wiley   +1 more source

Methionine Adenosyltransferase 1a (MAT1A) Enhances Cell Survival During Chemotherapy Treatment and is Associated with Drug Resistance in Bladder Cancer PDX Mice. [PDF]

, 2019
Bladder cancer is among the top ten most common cancers, with about ~380,000 new cases and ~150,000 deaths per year worldwide. Tumor relapse following chemotherapy treatment has long been a significant challenge towards completely curing cancer.
de Vere White, Ralph, Ghosh, Paramita M, He, Wei, Hum, Nicholas R, Loots, Gabriela G, Martin, Kelly A, Pan, Chong-Xian, Sebastian, Aimy, Siddiqui, Salma   +8 more
core   +2 more sources

MYCN Amplification in RB1‐Inactivated Retinoblastoma: Association With High‐Risk Features

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background MYCN amplification occurs in a subset of retinoblastoma cases, both with and without RB1 inactivation. It has been suggested that retinoblastomas with MYCN amplification represent a distinct entity with more aggressive clinical behavior.
Kyriaki Papaioannou, Regina Kubica, Karen Fischhuber, Jasmin Beygo, Madlen Reschke, Petra Ritter‐Sovinz, Eva Biewald, Petra Ketteler, Dietmar Lohmann, Deniz Kanber   +9 more
wiley   +1 more source

Role of immunotherapy in localized muscle invasive urothelial cancer

Therapeutic Advances in Medical Oncology, 2021
The standard treatment for non-metastatic muscle-invasive bladder cancer (MIBC) is cisplatin-based neoadjuvant chemotherapy followed by radical cystectomy or trimodality therapy with chemoradiation in select patients.
Jasmeet Kaur, Woonyoung Choi, Daniel M. Geynisman, Elizabeth R. Plimack, Pooja Ghatalia   +4 more
doaj   +1 more source